Carna Biosciences (TSE:4572) Total Debt per Share: 円96.23 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4572 Carna Biosciences Inc TSE:4572
27 GF Score
Price 円422.00
GF Value 円203.99
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Carna Biosciences Total Debt per Share?

Carna Biosciences TSE:4572 +0.24% 27 Total Debt per Share is 円96.23 as of Jun. 2026. GuruFocus rates TSE:4572 with a GF Score™ of 27/100 and a GF Value™ of 円203.99 (Significantly Overvalued). The stock has 7 warning signs investors should review.

円96.23 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Carna Biosciences's Total Debt Per Share for the quarter that ended in Jun. 2026 was 円96.23.

Carna Biosciences Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences Total Debt per Share Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.57 21.14 10.67 3.21 37.33

Carna Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 24.33 37.33 114.67 96.23
TSE:4572
27GF Score
Carna Biosciences Inc TSE:4572
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carna Biosciences Total Debt per Share Calculation

Carna Biosciences's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(697.6+16.9)/19.1
=37.33

Carna Biosciences's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(1,977.6+8.7)/20.6
=96.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of 円96.23 mean?
Carna Biosciences (TSE:4572) has a Total Debt per Share of 円96.23 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Carna Biosciences and its competitors.
Is Carna Biosciences' Total Debt per Share too high?
Carna Biosciences' current Total Debt per Share is 円96.23. Overall, Carna Biosciences has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Total Debt per Share compare to VRTX and REGN?
Carna Biosciences' Total Debt per Share of 円96.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Carna Biosciences and its competitors. Carna Biosciences's current Total Debt per Share is 円96.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円203.99, compared to a current price of 円422.00 — trading 106.9% above its estimated fair value. The current Total Debt per Share is 円96.23. Carna Biosciences' overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Total Debt per Share is 円96.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円422.00 is trading 106.9% above its estimated GF Value™ of 円203.99. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • Total Debt per Share: 円96.23
  • GF Value™: 円203.99 vs. price of 円422.00 (106.9% above fair value)
  • GF Score™: 27/100 with 7 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
27GF Score

Get the complete analysis for TSE:4572

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円422.00
Price
円203.99
GF Value